Alzheimer’s Disease: It’s Not All Bad News

20 Things To Know About Alzheimer's Disease

Please Help Support Alzheimer's Research Today! 

Your Alzheimer's donation will help billions live without it.

Improve Your Brain

Alzheimer's facts

DONATE NOW

(HDL levels greater than 55 milligrams)

Since the approval of four cholinesterase inhibitors in the 1990s and memantine in 2003, there have been no new treatments for Alzheimer’s disease, a condition that currently affects more than 35 million people worldwide. Against this backdrop, Paul Aisen of the University of California, San Diego, opened the 4th International Conference on Clinical Trials on Alzheimer's Disease (CTAD) on 3 November 2011 in San Diego, California. Aisen’s keynote address, now available on Alzforum tracks the evolution of Alzheimer’s disease trials from the first trials in 1986, to the above-mentioned approvals, to the many subsequent failures. Aisen plots a new phase forward, with researchers having a better handle on how to tackle the disease. Along with Aisen’s talk, Alzforum provides highlights of ongoing trials that were presented at CTAD.

Aisen, who heads the Alzheimer's Disease Cooperative Study (ADCS), a major academic sponsor of Alzheimer’s trials, said researchers have learned hard lessons about how to conduct such trials. For one thing, there is a growing consensus in the field that interventions are needed in the earliest stages of the disease, before the brain has suffered significant damage. But how? Some trials have already been conducted in people who have mild cognitive impairment (MCI)—in other words, who have some memory problems but no dementia. But these trials have all failed, and Aisen explains why. Since then, researchers have refined tools to identify those people with MCI who will most likely progress to Alzheimer’s. Continue to read: http://www.newswise.com

TODAY'S PHOTO

Vitamin D yogurt may improve cholesterol heart disease risk

Regular consumption of a vitamin D-fortified yogurt drink may improve cholesterol levels and markers of blood vessel functioning in diabetic people, according to new research. Read more: nutraingredients.com

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO).